December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.
165 citations
,
September 2013 in “Contemporary Clinical Trials” 6 citations
,
April 2021 in “Patient Preference and Adherence” Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
38 citations
,
January 2001 in “Neuroepidemiology” The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
3 citations
,
July 2025 in “International Immunopharmacology”
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
11 citations
,
January 2021 in “Breast Care” Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.
1 citations
,
October 2019 in “Medicina UPB” Multiple treatment comparison meta-analyses help doctors make better decisions by comparing different interventions.
September 2025 in “Value in Health”
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
October 2008 in “Australasian Journal of Dermatology” Medical practitioners need to understand basic statistics to properly evaluate clinical trials and avoid unethical designs.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
Adherence to finasteride treatment for prostate issues is generally low.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
April 2019 in “Biometrics” The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
March 2018 in “European Urology Supplements” Patients follow treatment well, but many change medicines; good information helps compliance.
February 2006 in “Inpharma Weekly” March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
1 citations
,
August 2021 in “Preventive Medicine” Not taking prescribed medications properly can lead to higher death rates from unrelated health conditions.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia” 60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
January 2020 in “Current trends in diagnosis & treatment” The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.